Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

키워드

참고문헌 (65)

1. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
2. "The National Health and Nutrition Survey, South Korea, 2020"[URL]
3. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
4. Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
5. Loomba R, "The 20% rule of NASH progression : the natural history of advanced fibrosis and cirrhosis caused by NASH", Hepatology, 70, pp.1885~1888 (2019)
6. Nakade Y, "Hepatocarcinogenesis in NASH", Gan To Kagaku Ryoho, 39, pp.693~697 (2012)
7. Stine JG, "Systematic review with meta-analysis : risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases", Aliment Pharmacol Ther, 48, pp.696~703 (2018)
8. Margini C, "The story of HCC in NAFLD : from epidemiology, across pathogenesis, to prevention and treatment", Liver Int, 36, pp.317~324 (2016)
9. Calle EE, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults", N Engl J Med, 348, pp.1625~1638 (2003)
10. Oh SW, "Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men : Korea national health insurance corporation study", J Clin Oncol, 23, pp.4742~4754 (2005)
11. Stickel F, "Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma : mechanisms and implications", Gut, 59, pp.1303~1307 (2010)
12. Auwerx J, "Leptin", Lancet, 351, pp.737~742 (1998)
13. Ikejima K, "Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat", Gastroenterology, 122, pp.1399~1410 (2002)
14. Dalamaga M, "The role of adiponectin in cancer : a review of current evidence", Endocr Rev, 33, pp.547~594 (2012)
15. Saxena NK, "Concomitant activation of the JAK", STAT, PI3K, Cancer Res, pp.2007, 67[DOI]
16. Vinciguerra M, "Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN", J Hepatol, 50, pp.1132~1141 (2009)
17. Chettouh H, "Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma", Liver Int, 35, pp.2203~2217 (2015)
18. Singh MK, "Diabetes and hepatocellular carcinoma : a pathophysiological link and pharmacological management", Biomed Pharmacother, 106, pp.991~1002 (2018)
19. Capone F, "The cytokinome profile in patients with hepatocellular carcinoma and type 2 diabetes", PLoS One, 10, pp.e0134594~ (2015)
20. Hay N, "Reprogramming glucose metabolism in cancer : can it be exploited for cancer therapy?", Nat Rev Cancer, 16, pp.635~649 (2016)
21. Hollenbach M, "The role of Glyoxalase-I(Glo-I), advanced glycation endproducts(AGEs), and their receptor(RAGE)in chronic liver disease and hepatocellular carcinoma(HCC)", Int J Mol Sci, 18, pp.2466~ (2017)
22. Zhao L, "The gut microbiota and obesity : from correlation to causality", Nat Rev Microbiol, 11, pp.639~647 (2013)
23. Yoshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
24. Dapito DH, "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", Cancer Cell, 21, pp.504~516 (2012)
25. Burza MA, "PNPLA3 I148M(rs738409)genetic variant is associated with hepatocellular carcinoma in obese individuals", Dig Liver Dis, 44, pp.1037~1041 (2012)
26. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
27. Petersen KF, "Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes", Diabetes, 54, pp.603~608 (2005)
28. Promrat K, "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis", Hepatology, 51, pp.121~129 (2010)
29. Keating SE, "Exercise and non-alcoholic fatty liver disease : a systematic review and metaanalysis", J Hepatol, 57, pp.157~166 (2012)
30. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
31. Baumeister SE, "Association between physical activity and risk of hepatobiliary cancers : a multinational cohort study", J Hepatol, 70, pp.885~892 (2019)
32. Baumeister SE, "Physical activity and the risk of liver cancer : a systematic review and meta-analysis of prospective studies and a bias analysis", J Natl Cancer Inst, 111, pp.1142~1151 (2019)
33. Turati F, "Mediterranean diet and hepatocellular carcinoma", J Hepatol, 60, pp.606~611 (2014)
34. Li WQ, "Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study", Hepatology, 60, pp.588~597 (2014)
35. Bogumil D, "High-quality diets are associated with reduced risk of hepatocellular carcinoma and chronic liver disease : the multiethnic cohort", Hepatol Commun, 3, pp.437~447 (2019)
36. European Association for the Study of the Liver, "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
37. Tamura T, "Coffee, green tea, and caffeine intake and liver cancer risk : a prospective cohort study", Nutr Cancer, 70, pp.1210~1216 (2018)
38. Tamura T, "Coffee consumption and liver cancer risk in Japan : a meta-analysis of six prospective cohort studies", Nagoya J Med Sci, 81, pp.143~150 (2019)
39. Montella M, "HCC, diet and metabolic factors : diet and HCC", Hepat Mon, 11, pp.159~162 (2011)
40. Erhardt A, "Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis(NASH)", Eur J Med Res, 16, pp.76~78 (2011)
41. Fedirko V, "Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations : a nested case-control study", Hepatology, 60, pp.1222~1230 (2014)
42. Sahasrabuddhe VV, "Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma", J Natl Cancer Inst, 104, pp.1808~1814 (2012)
43. Simon TG, "Association between aspirin use and risk of hepatocellular carcinoma", JAMA Oncol, 4, pp.1683~1690 (2018)
44. Myung Ji Goh, "Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?", Clinical and Molecular Hepatology, 28(3), pp.380~395 (2022), 대한간학회[DOI]
45. Simon TG, "Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.2776~2784 (2019)
46. Memel ZN, "Aspirin use is associated with a reduced incidence of hepatocellular carcinoma : a systematic review and metaanalysis", Hepatol Commun, 5, pp.133~143 (2021)
47. Zhang HL, "Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats", J Hepatol, 57, pp.803~812 (2012)
48. Singh S, "Antidiabetic medications and the risk of hepatocellular cancer : a systematic review and meta-analysis", Am J Gastroenterol, 108, pp.881~891 (2013)
49. El-Serag HB, "Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes", Gastroenterology, 136, pp.1601~1608 (2009)
50. Chiu HF, "Statin use and the risk of liver cancer : a population-based case-control study", Am J Gastroenterol, 106, pp.894~898 (2011)
51. McGlynn KA, "Statin use and risk of hepatocellular carcinoma in a U. S. population", Cancer Epidemiol, 38, pp.523~527 (2014)
52. Kim G, "Effect of statin on hepatocellular carcinoma in patients with type 2diabetes : a nationwide nested case-control study", Int J Cancer, 140, pp.798~806 (2017)
53. Islam MM, "Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies", Cancers(Basel), 12, pp.671~ (2020)
54. Facciorusso A, "Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis", Cancers(Basel), 12, pp.874~ (2020)
55. Hamelin BA, "Hydrophilicity", lipophilicity : relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors, 1998, pp.19, 26~37
56. Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
57. Yatsuji S, "Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C", J Gastroenterol Hepatol, 24, pp.248~254 (2009)
58. White DL, "Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review", Clin Gastroenterol Hepatol, 10, pp.1342~1359 (2012)
59. Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281 (2019)
60. Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.2296~2297 (2017)
61. Reig M, "Should patients with NAFLD", NASH be surveyed for HCC?, 2019, pp.103, 39~44
62. Kanwal F, "Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837 (2018)
63. Mittal S, "Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population", Clin Gastroenterol Hepatol, 13, pp.594~601 (2015)
64. Del Poggio P, "Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 12, pp.1927~1933 (2014)
65. Simmons O, "Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis", Aliment Pharmacol Ther, 45, pp.169~177 (2017)

관련 논문AI추천